Return to Calendar

Updates on Medication-Related Osteonecrosis of the Jaw (MRONJ)

Saturday, August 17, 2024
09:00 a.m. - 11:00 a.m.

Add to Calendar 2024-08-17 09:00:00 2024-08-17 11:00:00 Updates on Medication-Related Osteonecrosis of the Jaw (MRONJ) Medication-related osteonecrosis of the jaw (MRONJ) has become increasingly prevalent in our daily dental practice. In the U.S., approximately 10 million people have osteoporosis and 44 million have low bone mass. Additionally, there are approximately 1.8 million new cancer cases each year. Many cancer patients will undergo treatments such as radiation therapy, chemotherapy, surgical resection or combinations of the above. Advances in cancer treatment include the use of new medications to stabilize tumor invasion of the bone and increased utilization of concomitant chemotherapy and radiation therapy.MRONJ is an intraoral lesion caused by a severe adverse drug reaction and consists of progressive bone destruction in the maxillofacial region of patients. This can occur in patients undergoing long-term and/or high-dose therapy with bisphosphonates, RANKL inhibitors, antiangiogenic agents or mTOR inhibitors. Although rare, when it does occur it can pose significant challenges for oral healthcare providers. This webinar will help you to better understand MRONJ and the effects of these medications, and how to make informed decisions to improve your patients’ overall health.You Will LearnTo understand the uses of antiresorptive medications, such as bisphosphonatesTo discuss osteoporosis/osteopenia and how it relates to dentistryTo describe the latest information on MRONJ risks associated with different populations that dentists may encounterWho Should AttendThis informative webinar is designed for dentists, dental hygienists and dental assistants.Tuition: $125 Dentists; $95 Allied Dental ProfessionalsProgram: 9:00 am – 11:00 am (Pacific time)Format: Live, interactive webinar hosted on ZoomCredits: This activity is designated for 2 units of continuing education credit.PresenterEric Sung, DDS, received his dental degree at UCLA School of Dentistry and also completed a general practice residency at UCLA. Since that time, he has been on staff at Children’s Hospital in Los Angeles, City of Hope National Medical Center, VA Greater Los Angeles Health Care System, Kaiser Permanente and UCLA. Currently, Dr. Sung is a professor and chair of the Section of Special Patient Care and vice chair of the Division of Advanced Prosthodontics at UCLA School of Dentistry. He is also the holder of the Momentum Endowed Chair in Special Patient Care. He has lectured nationally and internationally and has multiple publications in peer-reviewed journals. Arthur A Dugoni School of Dentistry Arthur A Dugoni School of Dentistry America/Los_Angeles public

Medication-related osteonecrosis of the jaw (MRONJ) has become increasingly prevalent in our daily dental practice. In the U.S., approximately 10 million people have osteoporosis and 44 million have low bone mass. Additionally, there are approximately 1.8 million new cancer cases each year. Many cancer patients will undergo treatments such as radiation therapy, chemotherapy, surgical resection or combinations of the above. Advances in cancer treatment include the use of new medications to stabilize tumor invasion of the bone and increased utilization of concomitant chemotherapy and radiation therapy.

MRONJ is an intraoral lesion caused by a severe adverse drug reaction and consists of progressive bone destruction in the maxillofacial region of patients. This can occur in patients undergoing long-term and/or high-dose therapy with bisphosphonates, RANKL inhibitors, antiangiogenic agents or mTOR inhibitors. Although rare, when it does occur it can pose significant challenges for oral healthcare providers. This webinar will help you to better understand MRONJ and the effects of these medications, and how to make informed decisions to improve your patients’ overall health.

You Will Learn

To understand the uses of antiresorptive medications, such as bisphosphonates
To discuss osteoporosis/osteopenia and how it relates to dentistry
To describe the latest information on MRONJ risks associated with different populations that dentists may encounter

Who Should Attend

This informative webinar is designed for dentists, dental hygienists and dental assistants.

Tuition: $125 Dentists; $95 Allied Dental Professionals
Program: 9:00 am – 11:00 am (Pacific time)
Format: Live, interactive webinar hosted on Zoom
Credits: This activity is designated for 2 units of continuing education credit.

Presenter

Eric Sung, DDS, received his dental degree at UCLA School of Dentistry and also completed a general practice residency at UCLA. Since that time, he has been on staff at Children’s Hospital in Los Angeles, City of Hope National Medical Center, VA Greater Los Angeles Health Care System, Kaiser Permanente and UCLA. Currently, Dr. Sung is a professor and chair of the Section of Special Patient Care and vice chair of the Division of Advanced Prosthodontics at UCLA School of Dentistry. He is also the holder of the Momentum Endowed Chair in Special Patient Care. He has lectured nationally and internationally and has multiple publications in peer-reviewed journals.